A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

被引：0

作者：

Yanina Jansen

Vibeke Kruse

Jurgen Corthals

Kelly Schats

Pieter-Jan van Dam

Teofila Seremet

Carlo Heirman

Lieve Brochez

Mark Kockx

Kris Thielemans

Bart Neyns

机构：

[1] Universitair Ziekenhuis Brussel (UZ Brussel),Department of Medical Oncology

[2] Vrije Universiteit Brussel (VUB),Department of Medical Oncology

[3] Universitair Ziekenhuis Gent (UZ Gent),Laboratory of Molecular and Cellular Therapy and Dendritic Cell

[4] Vrije Universiteit Brussel,bank

[5] Histogenex NV,undefined

来源：

Cancer Immunology, Immunotherapy | 2020年 / 69卷

关键词：

TriMixDC-MEL; Melanoma; Adjuvant therapy; Dendritic vaccine;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2589 / 2598

页数：9